Tripair at EuroPCR 2024: Showcasing succesful 18 month follow-up data

May 2025 

At EuroPCR 2025, Coramaze’s vision to overcome the restrictive complexity of tricuspid regurgitation (TR) treatment with the genius of enabling simplicity came to life through a single, powerful story — that of Hannelie, one of the first patients treated with Tripair™.

Hannelie’s journey began years before EuroPCR. By the age of 35, she had undergone a mitral valve replacement, suffered three strokes, and developed torrential tricuspid regurgitation. She was unable to walk or care for herself, living with severe heart failure symptoms classified as NYHA Class IV. In 2023, Hannelie received a Tripair™ repair. At her 18-month follow-up — shortly before EuroPCR — she was assessed as NYHA Class I, reflecting a level of recovery equivalent to someone with a normally functioning heart.

Her story captured what Tripair™ aims to achieve: turning complexity into enabling simplicity, and making transformative outcomes possible for patients who otherwise have few or no treatment options.

Throughout the week in Paris, this story resonated deeply with physicians, industry leaders, and investors. Conversations focused not only on the technology itself but on the real-world impact it can deliver for patients like Hannelie. EuroPCR once again provided a powerful platform to connect with partners and collaborators who share the goal of making tricuspid repair more accessible worldwide.

Tripair™ is an investigational device and not commercially available in any geography. The opinions provided are those of the patients and physicians and are not intended to be claims related to the safety, effectiveness, or performance of the device.